Alector Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

AlectorDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -1.2% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 24.6% pro Jahr.

Wichtige Informationen

-1.2%

Wachstumsrate der Gewinne

9.2%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	24.6%
Eigenkapitalrendite	-106.7%
Netto-Marge	-290.7%
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Jul 11

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

May 18

Alector: Expect Phase 3 Data Next Year

Apr 16

These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Feb 27

Alector, Inc: A Newer Biotech Company With Big Potential

Jan 26

Alector: The GSK Deal Is A Major Value Add

Oct 29

We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate

Sep 27

Aufschlüsselung der Einnahmen und Ausgaben

Wie Alector Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:ALEC Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	55	-161	57	-6
31 Mar 24	96	-121	56	0
31 Dec 23	97	-130	57	0
30 Sep 23	96	-141	57	87
30 Jun 23	102	-143	58	87
31 Mar 23	126	-135	60	0
31 Dec 22	134	-133	61	0
30 Sep 22	133	-136	63	0
30 Jun 22	301	36	61	0
31 Mar 22	227	-29	60	0
31 Dec 21	207	-36	55	0
30 Sep 21	198	-33	51	0
30 Jun 21	21	-212	54	0
31 Mar 21	18	-202	56	0
31 Dec 20	21	-190	59	0
30 Sep 20	22	-169	58	0
30 Jun 20	19	-148	51	0
31 Mar 20	23	-127	43	0
31 Dec 19	21	-105	34	0
30 Sep 19	24	-92	27	0
30 Jun 19	28	-76	20	0
31 Mar 19	28	-62	15	0
31 Dec 18	28	-52	12	0
30 Sep 18	22	-45	10	0
30 Jun 18	15	-39	9	0
31 Mar 18	8	-35	8	0
31 Dec 17	4	-32	7	0
31 Dec 16	0	-15	2	0

Qualität der Erträge: ALEC ist derzeit unrentabel.

Wachsende Gewinnspanne: ALEC ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: ALEC ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 1.2% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von ALEC verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: ALEC ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (0.5%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: ALEC hat eine negative Eigenkapitalrendite (-106.71%), da es derzeit unrentabel ist.

Alector Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

New minor risk - Share price stability

Alector, Inc. Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Co-Founder recently sold US$129k worth of stock

Co-Founder recently sold US$129k worth of stock

Board Member recently sold US$228k worth of stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Co-Founder recently sold US$121k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold US$130k worth of stock

Consensus revenue estimates decrease by 37%, EPS upgraded

Co-Founder notifies of intention to sell stock

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Alector: Good Data, Huge Cash, No Near Term Catalyst

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold US$133k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)

Price target decreased by 12% to US$15.40

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002

Consensus revenue estimates increase by 244%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Price target decreased by 13% to US$14.33

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. Provides Revenue Guidance for the Year 2023

Co-Founder recently sold US$94k worth of stock

Consensus revenue estimates decrease by 24%

Consensus revenue estimates fall by 79%

Key Executive recently sold US$84k worth of stock

Price target decreased by 20% to US$16.94

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Full year 2022 earnings released: US$1.62 loss per share (vs US$0.45 loss in FY 2021)

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$21.44

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Alector, Inc. Announces Promotion of Clare Hunt to Chief People Officer

Alector, Inc. Announces Resignation of Robert King as Chief Development Officer

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Alector, Inc. Initiates Phase 1 Clinical Trial of Al044 for the Treatment of Alzheimer’s Disease

Consensus revenue estimates increase by 13%

Price target decreased to US$24.96

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alector, Inc Developing AL003 to Treat Patients with Alzheimer's Disease as One of Two Programs Pursuant to the Co-Development and Option Agreement

AbbVie ends partnership with Alector for Alzheimer’s candidate

Alector: Potential In Neurology And Cancer Treatments